Rani Therapeutics Holdings (RANI) Interest & Investment Income (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Interest & Investment Income of $412000.0 for Q1 2026, up 88.99% year-over-year from $218000.0 in Q1 2025, and up 7.29% quarter-over-quarter from $384000.0 in Q4 2025.
Rani Therapeutics Holdings (RANI) Interest & Investment Income (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Interest & Investment Income history runs 7 years deep, the most recent figure standing at $412000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 88.99% year-over-year to $412000.0; the TTM figure through Mar 2026 stood at $1.0 million (down 28.58% YoY), while the FY2025 annual figure was $827000.0, down 53.09% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $412000.0, up from $384000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $896000.0 in Q2 2023, with the low at $15000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $412000.0 (2026), against an average of $444117.6.
- The sharpest annual moves came in 2023 and 2025: Interest & Investment Income soared 5840.0% in 2023, then sank 83.57% in 2025.
- Rani Therapeutics Holdings' Interest & Investment Income stood at $818000.0 in 2022, then dropped by 17.48% to $675000.0 in 2023, then tumbled by 46.67% to $360000.0 in 2024, then advanced by 6.67% to $384000.0 in 2025, then increased by 7.29% to $412000.0 in 2026.
- Business Quant data shows RANI's Interest & Investment Income at $412000.0 in Q1 2026, $384000.0 in Q4 2025, and $68000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - | 415,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 415,000.00 |
| Mar 31, 2026 | 412,000.00 |
| Dec 31, 2025 | 384,000.00 |
| Sep 30, 2025 | 68,000.00 |
| Jun 30, 2025 | 158,000.00 |
| Mar 31, 2025 | 218,000.00 |
| Dec 31, 2024 | 360,000.00 |
| Sep 30, 2024 | 414,000.00 |
| Jun 30, 2024 | 439,000.00 |
| Mar 31, 2024 | 549,000.00 |
| Dec 31, 2023 | 675,000.00 |
| Sep 30, 2023 | 839,000.00 |
| Jun 30, 2023 | 896,000.00 |
| Mar 31, 2023 | 891,000.00 |
| Dec 31, 2022 | 818,000.00 |
| Sep 30, 2022 | 379,000.00 |
| Jun 30, 2022 | 35,000.00 |
| Mar 31, 2022 | 15,000.00 |
| Dec 31, 2021 | 16,000.00 |
| Sep 30, 2021 | 13,000.00 |